manag call reinforc thesi long-term
continu growth pt
last week host call interim cfo ron winowiecki head
consum healthcar america chca jeff needham head prescript
rx john wesolowski come away call assur
myriad move part within achiev low-single-digit revenu growth
potenti higher forese futur expect compani maintain
beach-head share chca difficult comp resolv rx recent restructur chci
begin produc result reiter buy rate share
chca segment remain well posit matur market key take-away
despit leader matur market chca still abil drive nt
lt growth segment macro trend us over-the-counter market allow privat label
product grow pace overal us over-the-counter market give floor around
growth anticip continu increment new product innov
capit broader rx-to-otc switch drive averag growth closer
rang time addit driver perrigo chca top
line expect year strong flu season benefit result margin
think expect privat label infant formula volum expans along softer
anim health comp follow restructur busi aid nt chca growth
rx wont compani appear commit rx busi
complex product like growth driver last sever month weve
waver think view prescript pharmaceut busi
howev spend time unit head wesolowski come away confid
segment well-run core part platform appear
busi continu focu complex product recent gxestrac
cream approv prove challeng win proair approv
manag appear confid approv launch come late
remain cautiou price compani expect around price
eros expect decent rx top-lin comp vs
beset continu price deflat custom consolid
amazon still eleph room chca rx excit
exist partnership amazon chca work launch
hous brand over-the-counter product amazon treat amazon
custom e-commerce overal new potenti class trade mani potenti
player enter market beyond over-the-counter appar held discuss
amazon rx side busi think one sever convers
amazon potenti rx industri partner note welcom
amazon potenti entri new custom rx believ amazon could
signific influenc marketplac
adjust estim tax updat move pt modestli
adjust revenu ep estim rais mix dcf ev/ebitda-
driven pt
note call attach transcript manag call also
avail pleas contact canaccord genuiti salesperson copi
price close busi januari
perrigo compani plc focus develop
distribut private-label over-the-counter drug brand over-the-counter drug
product private-label nutrit product gener
brand prescript drug activ pharmaceut
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
background
play uniqu space forefront qualiti afford
healthcar save consum bn annual
franchis
consum healthcar america chca bn busi us
mexico
grow tough market market growth
continu pick store brand share
grow north
rx south bn platform
great pipelin great asset durabl
theme call
segment grow market serv
chca adjust oper margin around manag
look sustain
chci adjust oper margin around
tri get high teen next year
flow strong best cash flow return
issu gener ocf
go move needl less
account dynam must oper new
see non-cash increas tax rate bp
uwe new ceo track record return sharehold valu
busi get acclim busi
around long time
spent major part format us store brand busi
often time default over-the-counter synonym chca
consum healthcar consist segment
store brand over-the-counter lion share chca
form full portfolio product sell point
one stop shop partner
buy unchang target price januari
lot molt around complex
technic regulatori standpoint
exclus market brand posit infant
ad acquisit
continu make us relev partner
optimist term continu grow
bit differ anim vs typic
portfolio brand platform
consist econom
provid consum real valu
higher price nation brand retail
get lot profit
canada over-the-counter infant nutrit store
valu orient busi
consum valu buy product suppli
buy product equival nation brand
price much cheaper nation brand
retail valu get lot profit
see import busi
competit retail landscap consum valu realli
seen growth collect market share custom
repres share term store brand busi come
unit volum share standpoint consider greater
aggreg store brand brand across retail
categori store brand repres biggest chunk everi
categori
big four categori import size growth
gi antacid lax
nicotin replac therapi import
today one largest store brand consum
health categori us
largest term market share
outsid new stori what best way model
track consum healthcar america busi also valu
proposit privat label us market key macro driver
term econom shelf gener speak consum
recogn lower price store brand walgreen brand over-the-counter
product vs compar nation brand
store brand retail make mayb margin
correspond nation brand
buy unchang target price januari
store brand driven aggress year
gener dollar share store brand somewher
mid level categori may drive
overal profit categori
case nrt dollar share store brand closer
well unit volum standpoint
primari mission drive store brand growth faster overal categori
today largest everi categori play
term competit kind compani see
neutral threat
one thing dont lack competit alway competit
make point largest manufactur market
store brand market market share
weve gener numer competitor core busi
acetaminophen aspirin monograph cough/cold item etc
product dont requir fda approv
lnk pl develop largest competitor
monograph product dollar size standpoint
year weve seen entrant focus anda
dr reddi lab teva actavi watson competitor
theyr opportunist competit strategi
current see interest gener compani get
otc/stor brand busi well
chca gross margin around oper margin low
key lever expand contract gross oper margin
need new launch drive margin upward
work retail counsel retail price even though
secondari still impactor overal price
competit certainli manifest price competit us
pace frequenc new product import lever well
difficult get price increas must look cost
save effici product oper
year ago oper margin taken busi
run level year look first month metric
model take top line growth model keep oper profil consist
keep model threshold
cough/cold/allergy/sinu flu season impact
think busi shake wors expect flu season
one four larg categori cca over-the-counter
broad portfolio product encompass solid dose liquid
posit impact rx over-the-counter switch one
brand switch repres increment growth without lot
buy unchang target price januari
inner nasal corticosteroid recent
what nice growth allergi temper import
import spring allergi fall allergi increas
import cough/cold season less today
strong cough/cold season bad flu standpoint
see strong po data strong cough/cold sale
biggest challeng keep demand cough/cold right
sever season isnt strong driver term perform
overal help busi make big deal
season go
still two order busi initi order pharmaci flu
season secondari order january/februari time-frame
less past
year ago youd signific order mention
retail manag inventori level differ
time manag
retail work real hard lean suppli chain
christma holiday stuff gone promot stuff activ
avail cough cold
amazon talk amazon strategi impact chca
partnership evolv time
see e-commerce opportun vs threat
critic e-commerce player one major
brick mortar custom e-commerce foundat compon
busi strategi
question e-commerce continu becom bigger class trade
us
today small slice distribut pie slice continu
e-commerce retail like amazon continu grow space
approach busi like year retail
custom want everyon strateg partner choic
work amazon across coupl differ brand goal
partner strateg import drive
alpha player us market natur
provid amazon
also regulatori advantag provid
broad array dosag form
know margin structur
goal end day grow store brand share
would good grow e-commerce anoth
saw hire plant manag ohio indic addit shift
expect volum expans infant formula
busi continu grow biggest reason
compar store brand over-the-counter lot runway us
continu grow store brand share
grow retail
continu good new product activ
busi optimist bullish
buy unchang target price januari
brand core focu chci work either expand
offer core market potenti bring intern product us
easi one answer
challeng transfer product one part world
inevit reformul necessari
opportun certain multi-national custom
go forward abl unlock transfer product
mayb longer rang strategi potenti creat
valu brand platform across europ augment brand busi
weve discuss
anim driver busi also notic
reposit busi describ chang
expect action impact segment go forward
chose get busi
clear growth trend consumpt companion
pet ownership continu grow
also saw opportun product introduc
candidli pace switch over-the-counter hasnt gone quickli expect
see opportun go forward
custom relationship place abl leverag anim
reason shouldnt abl succeed mass market
one thing would like focu histori industri
first employe rx side abl build train
team
abl bring real smart team brought everyth intern
realli great experi
dont want everi product hyper competit
initi start focu extend topic
thing difficult develop space
clinic studi
week got three approv week diversifi portfolio
lot compani heavi turnov product must
continu approv maintain busi
top doesnt fall product come
none top product drive segment sale
portfolio oral solid
dont count growth driver
focu opportunist product smaller scope tough
manufactur longer runway
buy unchang target price januari
talk bit pharma pipelin saw estrac epiduo
approv week wonder speak opportun set new
launch beyond
estrac difficult expens product bring market
develop four year
partner product measur risk
first file product launch around
time period ahead schedul
assum tradit gross profit partner product
proair want get thought updat time product
issu resolv challeng hinder/discourag develop
futur inhal product
expens manufactur bring market challeng hinder
us test resolv
dont expect hyper competit market even though
brand signific one
us get share market go problem
take measur approach come inventori build want
make sure good product
also manufactur devic product
api associ
launch back half year feel confid get
potenti impact heard intermountain enter
sell institut channel thru buy group small
portion less
gener entiti major impact sale
think on-notic type commun brand compani
think focus oncolog type drug
like help counter suppli issu hospit base product
type product compet
gener price thought think macro challeng
price subsid compani need adopt portfolio specif strategi
combat price deflat price continuum
credit saw eros consolid happen anyon
dont think anoth consolid happen
eros ye alway eros busi
think heavier eros think
us long runway eros factor littl
margin outsid price lever expand margin
new product driver margin well front end back
end new product launch
buy unchang target price januari
go back strategi want investor think
extend topic strategi nich model design win
divers portfolio none product make
sale
thought prescript pharmaceut continu compon
portfolio strength get larger associ
advantag could divis independ entiti part larger
talk synergi two busi
rx over-the-counter strategi partner choic whether product rx
over-the-counter
product potenti make switch
choic retail
abl offer new market option
allergi went rx over-the-counter doctor still write
prescript product switch
creat hous label still reimburs
medicaid parti insur
distribut center synergi ship product
truck
group interact whole group support over-the-counter side
group gener medicaid complianc rx
share over-the-counter side help compani save
tradit gener compani add someth market
answer cant think anyth
how tone fda chang gottlieb new leadership
believ tone chang help us welcom speed approv
launch product quicker
far havent seen mayb littl bit
think still earli process new admin
think chang happen time
seen histor slowdown approv start year blame
chang defin element impur part usp requir
affect shut-down slow anyth
januari februari time frame alway bit slower
alway see heavi approv novemb decemb
closeout year
far thing dont see anyth els affect
need start fill bucket file though that
focu next month get file
could amazon entri prescript pharmaceut market affect
busi prospect keep night
first convers w/amazon month welcom
come market
buy unchang target price januari
would love new custom come
sure time anoth competitor market
would healthi
fda compound product see impact
awar product compound
someth promot suggest market
core compet gener busi would
like add given blank check
good identifi opportunist product chosen good
last year first patch approv that space wed like
inject great lot competit would rather partner
side vs buy
like inhal space might better partner approach
opportun capit disloc gener industri
talent facil wise
seen facil come on-line lot oral solid base
dont need capac us
fortun find talent west michigan
strong talent work pool
great reput custom peer miss
someth abil fill easili
gpha aam meet think key theme
longer member gpha
believ discuss dtc type pill talk
think gener compani talk
think overal model chang sure
convers weekli assum topic cover
meet
chanc expand gener global
dont talk much transfer ou
gener industri exec sent email say gener dead assum
disagre would respond email
approv week potenti launch come feel pretti
great busi
challeng clearli dead
npv portfolio strongest ever
least gener aliv well
prescript written substitut gener
expect pend acquisit acorn impact market compet
differ busi model
dont problem what go pend long time
far product compet deliv concern
buy unchang target price januari
give us updat cost cut program find
go well announc last year cost save initi
achiev complet
busi execut standpoint balanc scale agil
increas increas oper expens
give color guidanc februari
price target deriv blend dcf wacc termin
growth lead valuat weight around forward
ev/ebitda gener group averag estim lead
valuat weight around
risk rate price target
long-term chca growth depend rx-to-otc shift new categori
usual drive low-single-digit growth consum health america
chca busi though increas privat label uptak off-set somewhat retail
price pressur believ signific sustain growth chca busi
driven addit categori switch prescript over-the-counter condit
littl control brand pharma compani fda
resist move statin topic pain nsaid overact bladder treatment
erectil dysfunct product migrain product asthma inhal ophthalm
allergi dry-ey treatment over-the-counter could see pressur chca segment
despit domin share chca addit competitor start gain
long held domin share private-label over-the-counter market recent
over-the-counter switch seen steadi competit tradit prescript gener
compani seek gain traction over-the-counter retail typic assumpt
share given pl over-the-counter market longer guarante
believ continu increment competit could significantli slow perrigo
consum health intern chci busi may prove drag
take correct action segment follow challeng
belgian busi believ growth could slow segment follow brexit
potenti fx challeng continu restructur busi
buy unchang target price januari
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price januari
million usd except per share non-gaaprevenueconsum healthcar healthcar profit oper expensescost ipr oper expensestysabri chang expens expense/ incom sale invest -- -- -- -- -- -- -- -loss extinguish non-oper net incomeincom tax analysisbas per share share figur perrigo dcf model
buy unchang target price januari
million usd except per share healthcar healthcar depreci amort exclud chang growth estim period long-term period net debt share outstand input perrigo compani
